Photo: David A. Rizzieri, MD
David A. Rizzieri, MD
Year elected: 2009
Current membership category: Senior
Duke University Medical Center
2400 Pratt Street
Durham, NC 27710
United States of America
Phone: 919 668 1040
Facsimile: 919 668 1091

Biographical statement

Dr. David Rizzieri has focused his clinical/translational research efforts on the care and treatment of patients with leukemia or lymphoma. He is a designated ‘Scholar in Clinical Research’ by the Leukemia and Lymphoma Society and is chair, co-chair or correlative science chair of various CALGB trials involving those with Burkitt’s, MDS, or follicular lymphoma. He has designed novel approaches for non-myeloablative allogeneic therapy to optimize a less toxic regimen for transplant of patients using haplo-identical donors, followed by immune modulating strategies to improve outcomes. In addition, he has led the development of new targeted therapies including anti-stromal directed therapy in lymphoma using a radiolabeled monoclonal antibody to tenascin, anti CD123 directed therapy in leukemia, and various pathway inhibitors. While developing his research program, he has led the growth of clinical/translational research in this field at Duke University and directs the institution's efforts to coordinate studies in this field to promote novel therapies for patients with these illnesses.

Institutional affiliations

Duke University School of Medicine (Primary)
Scott M. Palmer, MD, MHS is the representative at this institution.